Vision, Integrity, Expertise
Soligenix, Inc. is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications.
Thursday, December 05, 2013Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Monday, December 02, 2013Soligenix Announces Initiation of a Phase 2 Clinical Trial of orBec® for the Treatment of Chronic GI GVHD Clinical Trial Supported by $300,000 NCI Grant
Thursday, November 21, 2013Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Partnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.